Company / SG&A Expense
Aurinia Pharmaceuticals Inc. SG&A Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$101.8M
FY2025
5-year range
$22.3M / $195.0M
FY2021-FY2025
Trend
-40.8%
vs FY2024
Sector context
#112 of 213
Health Care
What the data says
At $102M, Aurinia Pharmaceuticals Inc.'s sg&a expense ranks #102 of 213 in the Health Care sector. SG&A Expense has fluctuated over the past 8 years, ranging from $14M in FY2018 to $195M in FY2023.
Based on SEC 10-K filings.
$102M in FY2025 with a 5-year CAGR of +0.9%.
Improved from $195M to $102M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +1.5%
- 5-Year CAGR
- +0.9%
- 10-Year CAGR
- -
Sector benchmark
#102 of 213 in Health CareTop 47% of 213This company $101.8M Sector average $722.3M
▼
-85.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +0.9%, indicating consistent growth.
- In FY2025, sg&a expense decreased 40.8% year-over-year.
- Ranks #112 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2023.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $101.8M | -40.8% |
| FY2024 | $172.0M | -11.8% |
| FY2023 | $195.0M | +100.4% |
| FY2022 | $97.3M | +336.3% |
| FY2021 | $22.3M | -77.1% |
| FY2020 | $97.3M | +336.3% |
| FY2019 | $22.3M | +62.8% |
| FY2018 | $13.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026